Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
Sarepta Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Sarepta Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $111.01M. For fiscal 2025 it was -$205.48M. The highest annual figure on record is $107.47M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$205.48M | – |
| FY2024 | Dec 31, 2024 | -$205.79M | – |
| FY2023 | Dec 31, 2023 | -$500.99M | – |
| FY2022 | Dec 31, 2022 | -$325.35M | – |
| FY2021 | Dec 31, 2021 | -$443.17M | -512.4% |
| FY2020 | Dec 31, 2020 | $107.47M | – |
| FY2019 | Dec 31, 2019 | -$456.46M | – |
| FY2018 | Dec 31, 2018 | -$388.66M | – |
| FY2017 | Dec 31, 2017 | -$232.00M | – |
| FY2016 | Dec 31, 2016 | -$245.82M | – |
| FY2015 | Dec 31, 2015 | -$149.47M | – |
| FY2014 | Dec 31, 2014 | -$128.54M | – |
| FY2013 | Dec 31, 2013 | -$64.70M | – |
| FY2012 | Dec 31, 2012 | -$29.69M | – |
| FY2011 | Dec 31, 2011 | -$23.68M | – |
| FY2010 | Dec 31, 2010 | -$15.21M | – |
| FY2009 | Dec 31, 2009 | -$8.80M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $197.07M | -24.6% |
| Q1 FY2026 | Mar 31, 2026 | -$202.68M | – |
| Q4 FY2025 | Dec 31, 2025 | $131.21M | +42.5% |
| Q3 FY2025 | Sep 30, 2025 | -$14.59M | – |
| Q2 FY2025 | Jun 30, 2025 | $261.34M | +1649.0% |
| Q1 FY2025 | Mar 31, 2025 | -$583.44M | – |
| Q4 FY2024 | Dec 31, 2024 | $92.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$70.70M | – |
| Q2 FY2024 | Jun 30, 2024 | $14.94M | – |
| Q1 FY2024 | Mar 31, 2024 | -$242.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$54.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$114.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$122.23M | – |
| Q1 FY2023 | Mar 31, 2023 | -$209.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$92.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$64.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$66.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$101.18M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$124.33M | – |
| Q2 FY2021 | Jun 30, 2021 | -$109.15M | – |
| Q1 FY2021 | Mar 31, 2021 | -$180.37M | -128.7% |
| Q4 FY2020 | Dec 31, 2020 | -$174.54M | – |
| Q3 FY2020 | Sep 30, 2020 | -$238.19M | – |
| Q2 FY2020 | Jun 30, 2020 | -$107.60M | – |
| Q1 FY2020 | Mar 31, 2020 | $627.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -$163.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$67.43M | – |
| Q2 FY2019 | Jun 30, 2019 | -$79.00M | – |
| Q1 FY2019 | Mar 31, 2019 | -$146.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$122.42M | – |
| Q3 FY2018 | Sep 30, 2018 | -$113.32M | – |
| Q2 FY2018 | Jun 30, 2018 | -$117.25M | – |
| Q1 FY2018 | Mar 31, 2018 | -$35.67M | – |
| Q4 FY2017 | Dec 31, 2017 | -$31.06M | – |
| Q3 FY2017 | Sep 30, 2017 | -$57.90M | – |
| Q2 FY2017 | Jun 30, 2017 | -$85.15M | – |
| Q1 FY2017 | Mar 31, 2017 | -$57.89M | – |
| Q4 FY2016 | Dec 31, 2016 | -$81.23M | – |
| Q3 FY2016 | Sep 30, 2016 | -$60.62M | – |
See a number that looks wrong?